Q2 2018 Neurocrine Biosciences Inc Earnings Call
Conference Call Neurocrine Biosciences Inc
Neurocrine Biosciences Inc Conference call will be held on Jul 31, 2018. During the earnings conference call's session Neurocrine Biosciences Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Neurocrine Biosciences Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We were originally incorporated in California in January 1992 and were reincorporated in Delaware in May 1996. We discover and develop innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through our novel R&D platform, focused on neurological and endocrine based diseases and disorders. Our two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine) a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. We intend to maintain certain commercial rights to our VMAT2 inhibitor and evolve into a fully-integrated pharmaceutical company.Read more Conference Call